Shi Meiqi

5PUBLICATIONS
32CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 19, 2026
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Bo Shen, Chun Wang, Liqin Zhang

|Nov 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Dingzhi Huang, Gen Lin, Qian Chu

|Oct 16, 2023
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.

Li Wang, Fei Quan, Zhen Guo

|Sep 27, 2021
Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors.

Zhu Wenbo, Zhao Qing, Wang Li

|Aug 16, 2021
Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication.

Yizhuo Zhao, Wei Peng, Muhammad Abbas

Pageof 1

Frequent Collaborators

2 joint publications

Bo Shen

1 joint publications

Fei Quan

1 joint publications

Dingzhi Huang

1 joint publications

Gen Lin